NCT07635056

Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2026-07Est. Completion: 2031-06

Enrollment target: 20 participants

Locations

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Contact

Caitlin Cottrell, BSN, RNCaitlin.cottrell@cchmc.org 513-803-7039

Other microbiome trials you might be interested in

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI StudyPhase 1WITHDRAWN

Constitutional Mismatch Repair Deficiency SyndromeHematopoietic and Lymphoid Cell NeoplasmLynch SyndromeRecurrent LymphomaRecurrent Malignant Solid NeoplasmRecurrent NeuroblastomaRecurrent Primary Central Nervous System NeoplasmRefractory LymphomaRefractory Malignant Solid NeoplasmRefractory NeuroblastomaRefractory Primary Central Nervous System NeoplasmXeroderma Pigmentosum

This phase Ib trial investigates the side effects of the combination of nivolumab and ipilimumab, and to see how well th…

Palo Alto, United StatesCompleted Jun 21, 2022

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.